Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small cell lung cancer receiving 1st-line chemotherapy: a Phase 1b/randomized Phase 2 trial.

Weiss JM, Csoszi T, Maglakelidze M, Hoyer RJ, Beck JT, Gomez MD, Lowczak A, Aljumaily R, Lima CMR, Boccia RV, Hanna W, Nikolinakos P, Chiu VK, Owonikoko TK, Schuster SR, Hussein MA, Richards DA, Sawrycki P, Bulat I, Hamm JT, Hart LL, Adler S, Antal JM, Lai AY, Sorrentino JA, Yang Z, Malik RK, Morris SR, Roberts PJ, Dragnev KH; G1T28-02 Study Group.

Ann Oncol. 2019 Aug 27. pii: mdz278. doi: 10.1093/annonc/mdz278. [Epub ahead of print]

PMID:
31504118
2.

An extended overall survival analysis of pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced non-squamous non-small cell lung cancer.

Afzal MZ, Dragnev KH, Shirai K.

Ann Transl Med. 2019 Mar;7(Suppl 1):S53. doi: 10.21037/atm.2019.03.09. No abstract available.

3.

Small-cell lung cancer growth inhibition: synergism between NMDA receptor blockade and chemotherapy.

North WG, Liu F, Dragnev KH, Demidenko E.

Clin Pharmacol. 2019 Jan 23;11:15-23. doi: 10.2147/CPAA.S183885. eCollection 2019.

4.

Hospitalization and Survival of Medicare Patients Treated With Carboplatin Plus Paclitaxel or Pemetrexed for Metastatic, Nonsquamous, Non-Small Cell Lung Cancer.

Brooks GA, Austin AM, Uno H, Dragnev KH, Tosteson ANA, Schrag D.

JAMA Netw Open. 2018 Oct 5;1(6):e183023. doi: 10.1001/jamanetworkopen.2018.3023.

5.

A phase I/II study of bexarotene with carboplatin and weekly paclitaxel for the treatment of patients with advanced non-small cell lung cancer.

Dragnev KH, Whyman JD, Hahn CK, Kebbekus PE, Kokko SF, Bhatt SM, Rigas JR.

J Thorac Dis. 2018 Sep;10(9):5531-5537. doi: 10.21037/jtd.2018.09.10.

6.

The role of a palliative care intervention in moderating the relationship between depression and survival among individuals with advanced cancer.

Prescott AT, Hull JG, Dionne-Odom JN, Tosteson TD, Lyons KD, Li Z, Li Z, Dragnev KH, Hegel MT, Steinhauser KE, Ahles TA, Bakitas MA.

Health Psychol. 2017 Dec;36(12):1140-1146. doi: 10.1037/hea0000544. Epub 2017 Oct 19.

7.

Clinical Genotyping of Non-Small Cell Lung Cancers Using Targeted Next-Generation Sequencing: Utility of Identifying Rare and Co-mutations in Oncogenic Driver Genes.

Tafe LJ, Pierce KJ, Peterson JD, de Abreu F, Memoli VA, Black CC, Pettus JR, Marotti JD, Gutmann EJ, Liu X, Shirai K, Dragnev KH, Amos CI, Tsongalis GJ.

Neoplasia. 2016 Sep;18(9):577-83. doi: 10.1016/j.neo.2016.07.010.

8.

Family Caregiver Depressive Symptom and Grief Outcomes From the ENABLE III Randomized Controlled Trial.

Dionne-Odom JN, Azuero A, Lyons KD, Hull JG, Prescott AT, Tosteson T, Frost J, Dragnev KH, Bakitas MA.

J Pain Symptom Manage. 2016 Sep;52(3):378-85. doi: 10.1016/j.jpainsymman.2016.03.014. Epub 2016 Jun 3.

9.

The Pitfalls of Companion Diagnostics: Evaluation of Discordant EGFR Mutation Results from a Clinical Laboratory and a Central Laboratory.

Turner SA, Peterson JD, Pettus JR, de Abreu FB, Amos CI, Dragnev KH, Tsongalis GJ.

J Mol Diagn. 2016 May;18(3):331-335. doi: 10.1016/j.jmoldx.2015.12.004. Epub 2016 Mar 7.

10.

Reply to R.A. Ferrer et al and B.W. Corn.

Bakitas M, Dionne-Odom JN, Lyons KD, Dragnev KH.

J Clin Oncol. 2015 Dec 10;33(35):4230-1. doi: 10.1200/JCO.2015.63.4337. Epub 2015 Oct 12. No abstract available.

PMID:
26460297
11.

Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center.

Tafe LJ, Gorlov IP, de Abreu FB, Lefferts JA, Liu X, Pettus JR, Marotti JD, Bloch KJ, Memoli VA, Suriawinata AA, Dragnev KH, Fadul CE, Schwartz GN, Morgan CR, Holderness BM, Peterson JD, Tsongalis GJ, Miller TW, Chamberlin MD.

Oncologist. 2015 Sep;20(9):1011-8. doi: 10.1634/theoncologist.2015-0097. Epub 2015 Jul 23.

12.

Early Versus Delayed Initiation of Concurrent Palliative Oncology Care: Patient Outcomes in the ENABLE III Randomized Controlled Trial.

Bakitas MA, Tosteson TD, Li Z, Lyons KD, Hull JG, Li Z, Dionne-Odom JN, Frost J, Dragnev KH, Hegel MT, Azuero A, Ahles TA.

J Clin Oncol. 2015 May 1;33(13):1438-45. doi: 10.1200/JCO.2014.58.6362. Epub 2015 Mar 23.

13.

Benefits of Early Versus Delayed Palliative Care to Informal Family Caregivers of Patients With Advanced Cancer: Outcomes From the ENABLE III Randomized Controlled Trial.

Dionne-Odom JN, Azuero A, Lyons KD, Hull JG, Tosteson T, Li Z, Li Z, Frost J, Dragnev KH, Akyar I, Hegel MT, Bakitas MA.

J Clin Oncol. 2015 May 1;33(13):1446-52. doi: 10.1200/JCO.2014.58.7824. Epub 2015 Mar 23.

14.

ALK-rearranged adenosquamous lung cancer presenting as squamous cell carcinoma: a potential challenge to histologic type triaging of NSCLC biopsies for molecular studies.

Dragnev KH, Gehr G, Memoli VA, Tafe LJ.

Clin Lung Cancer. 2014 May;15(3):e37-40. doi: 10.1016/j.cllc.2014.01.003. Epub 2014 Jan 18. No abstract available.

PMID:
24524823
15.

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.

Roengvoraphoj M, Tsongalis GJ, Dragnev KH, Rigas JR.

Cancer Treat Rev. 2013 Dec;39(8):839-50. doi: 10.1016/j.ctrv.2013.05.001. Epub 2013 Jun 12. Review.

16.

Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer.

Ma T, Galimberti F, Erkmen CP, Memoli V, Chinyengetere F, Sempere L, Beumer JH, Anyang BN, Nugent W, Johnstone D, Tsongalis GJ, Kurie JM, Li H, Direnzo J, Guo Y, Freemantle SJ, Dragnev KH, Dmitrovsky E.

Mol Cancer Ther. 2013 Aug;12(8):1545-55. doi: 10.1158/1535-7163.MCT-12-0933. Epub 2013 May 16.

17.

Trimodality therapy for stage II-III carcinoma of the esophagus: a dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy.

Wood MD, Zaki BI, Gordon SR, Sutton JE Jr, Lisovsky M, Gui J, Bubis JA, Dragnev KH, Rigas JR.

J Thorac Oncol. 2013 Apr;8(4):487-94. doi: 10.1097/JTO.0b013e3182829bf3.

18.

A phase I trial and in vitro studies combining ABT-751 with carboplatin in previously treated non-small cell lung cancer patients.

Ma T, Fuld AD, Rigas JR, Hagey AE, Gordon GB, Dmitrovsky E, Dragnev KH.

Chemotherapy. 2012;58(4):321-9. doi: 10.1159/000343165. Epub 2012 Nov 12.

19.

Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations.

Galimberti F, Busch AM, Chinyengetere F, Ma T, Sekula D, Memoli VA, Dragnev KH, Liu F, Johnson KC, Guo Y, Freemantle SJ, Andrew AS, Greninger P, Robbins DJ, Settleman J, Benes C, Dmitrovsky E.

Int J Oncol. 2012 Nov;41(5):1751-61. doi: 10.3892/ijo.2012.1599. Epub 2012 Aug 22.

20.

A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer.

Bayliss TJ, Smith JT, Schuster M, Dragnev KH, Rigas JR.

Expert Opin Biol Ther. 2011 Dec;11(12):1663-8. doi: 10.1517/14712598.2011.627850. Epub 2011 Oct 13. Review.

PMID:
21995322
21.

Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.

Dragnev KH, Ma T, Cyrus J, Galimberti F, Memoli V, Busch AM, Tsongalis GJ, Seltzer M, Johnstone D, Erkmen CP, Nugent W, Rigas JR, Liu X, Freemantle SJ, Kurie JM, Waxman S, Dmitrovsky E.

Cancer Prev Res (Phila). 2011 Jun;4(6):818-28. doi: 10.1158/1940-6207.CAPR-10-0376.

22.

High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer.

Petty WJ, Voelzke WR, Urbanic JJ, Varela VA, Waller LL, Swift CB, Graham RM, Memoli VA, Dragnev KH.

Lung Cancer. 2011 Dec;74(3):384-91. doi: 10.1016/j.lungcan.2011.04.004. Epub 2011 May 8.

PMID:
21555162
23.

Pemetrexed in advanced non-small-cell lung cancer.

Fuld AD, Dragnev KH, Rigas JR.

Expert Opin Pharmacother. 2010 Jun;11(8):1387-402. doi: 10.1517/14656566.2010.482560. Review.

PMID:
20446853
24.

A dose escalation trial of biweekly docetaxel and gemcitabine with filgrastim or pegfilgrastim for the treatment of patients with advanced solid tumors.

Dragnev KH, Hardin SB, Pipas JM, Davis TH, Rigas JR.

Chemotherapy. 2010;56(2):135-41. doi: 10.1159/000313526. Epub 2010 Apr 20.

PMID:
20407240
25.

MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors.

Liu X, Sempere LF, Ouyang H, Memoli VA, Andrew AS, Luo Y, Demidenko E, Korc M, Shi W, Preis M, Dragnev KH, Li H, Direnzo J, Bak M, Freemantle SJ, Kauppinen S, Dmitrovsky E.

J Clin Invest. 2010 Apr;120(4):1298-309. doi: 10.1172/JCI39566. Epub 2010 Mar 8.

26.

In search of the magic bullet.

Dragnev KH.

Transl Res. 2009 Jun;153(6):261-2. doi: 10.1016/j.trsl.2009.03.002. Epub 2009 Mar 27. No abstract available.

PMID:
19446278
27.

Uncovering growth-suppressive MicroRNAs in lung cancer.

Liu X, Sempere LF, Galimberti F, Freemantle SJ, Black C, Dragnev KH, Ma Y, Fiering S, Memoli V, Li H, DiRenzo J, Korc M, Cole CN, Bak M, Kauppinen S, Dmitrovsky E.

Clin Cancer Res. 2009 Feb 15;15(4):1177-83. doi: 10.1158/1078-0432.CCR-08-1355.

28.

Cyclin degradation for cancer therapy and chemoprevention.

Freemantle SJ, Liu X, Feng Q, Galimberti F, Blumen S, Sekula D, Kitareewan S, Dragnev KH, Dmitrovsky E.

J Cell Biochem. 2007 Nov 1;102(4):869-77. Review.

PMID:
17868090
29.

A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer.

Dragnev KH, Petty WJ, Shah SJ, Lewis LD, Black CC, Memoli V, Nugent WC, Hermann T, Negro-Vilar A, Rigas JR, Dmitrovsky E.

Clin Cancer Res. 2007 Mar 15;13(6):1794-800.

30.

Uncovering novel targets for cancer chemoprevention.

Dragnev KH, Feng Q, Ma Y, Shah SJ, Black C, Memoli V, Nugent W, Rigas JR, Kitareewan S, Freemantle S, Dmitrovsky E.

Recent Results Cancer Res. 2007;174:235-43. Review.

PMID:
17302201
31.

Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing.

Thomas RK, Nickerson E, Simons JF, Jänne PA, Tengs T, Yuza Y, Garraway LA, LaFramboise T, Lee JC, Shah K, O'Neill K, Sasaki H, Lindeman N, Wong KK, Borras AM, Gutmann EJ, Dragnev KH, DeBiasi R, Chen TH, Glatt KA, Greulich H, Desany B, Lubeski CK, Brockman W, Alvarez P, Hutchison SK, Leamon JH, Ronan MT, Turenchalk GS, Egholm M, Sellers WR, Rothberg JM, Meyerson M.

Nat Med. 2006 Jul;12(7):852-5. Epub 2006 Jun 25. Erratum in: Nat Med. 2006 Oct;12(10):1220.

PMID:
16799556
32.

The retinoic acid paradox in cancer chemoprevention.

Freemantle SJ, Dragnev KH, Dmitrovsky E.

J Natl Cancer Inst. 2006 Apr 5;98(7):426-7. No abstract available.

PMID:
16595769
33.

Bexarotene and erlotinib for aerodigestive tract cancer.

Dragnev KH, Petty WJ, Shah S, Biddle A, Desai NB, Memoli V, Rigas JR, Dmitrovsky E.

J Clin Oncol. 2005 Dec 1;23(34):8757-64.

PMID:
16314636
34.

A novel retinoic acid receptor beta isoform and retinoid resistance in lung carcinogenesis.

Petty WJ, Li N, Biddle A, Bounds R, Nitkin C, Ma Y, Dragnev KH, Freemantle SJ, Dmitrovsky E.

J Natl Cancer Inst. 2005 Nov 16;97(22):1645-51.

PMID:
16288117
35.

Acute monocular blindness resulting from transformation of von Recklinghausen's neurofibromatosis to malignant melanocytic schwannomas.

Wrzesinski SH, Dragnev KH, Mayo LK, Harris BT, Marotti JD.

J Neurooncol. 2006 Feb;76(3):277-81.

PMID:
16244794
36.

Docetaxel in the treatment of esophageal cancer.

Rigas JR, Dragnev KH, Bubis JA.

Semin Oncol. 2005 Apr;32(2 Suppl 4):S39-51. Review.

PMID:
16015553
37.

Focal paraneoplastic limbic encephalitis presenting as orgasmic epilepsy.

Fadul CE, Stommel EW, Dragnev KH, Eskey CJ, Dalmau JO.

J Neurooncol. 2005 Apr;72(2):195-8.

PMID:
15926002
38.

Nonclassical retinoids and lung carcinogenesis.

Dragnev KH, Petty WJ, Ma Y, Rigas JR, Dmitrovsky E.

Clin Lung Cancer. 2005 Jan;6(4):237-44. Review.

PMID:
15694016
39.

Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene.

Rigas JR, Dragnev KH.

Oncologist. 2005 Jan;10(1):22-33. Review.

40.

Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers.

Petty WJ, Dragnev KH, Memoli VA, Ma Y, Desai NB, Biddle A, Davis TH, Nugent WC, Memoli N, Hamilton M, Iwata KK, Rigas JR, Dmitrovsky E.

Clin Cancer Res. 2004 Nov 15;10(22):7547-54.

41.

Microarray analyses uncover UBE1L as a candidate target gene for lung cancer chemoprevention.

Pitha-Rowe I, Petty WJ, Feng Q, Koza-Taylor PH, Dimattia DA, Pinder L, Dragnev KH, Memoli N, Memoli V, Turi T, Beebe J, Kitareewan S, Dmitrovsky E.

Cancer Res. 2004 Nov 1;64(21):8109-15.

42.

Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy.

Dragnev KH, Pitha-Rowe I, Ma Y, Petty WJ, Sekula D, Murphy B, Rendi M, Suh N, Desai NB, Sporn MB, Freemantle SJ, Dmitrovsky E.

Clin Cancer Res. 2004 Apr 1;10(7):2570-7.

43.

The role of docetaxel in nonplatinum-based combination chemotherapy for non-small-cell lung cancer.

Petty WJ, Rothmann J, Dragnev KH, Rigas JR.

Clin Lung Cancer. 2002 May;3 Suppl 2:S12-6.

PMID:
14720342
44.

Retinoid targets in cancer therapy and chemoprevention.

Dragnev KH, Petty WJ, Dmitrovsky E.

Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S150-6. Review.

PMID:
14508093
45.

Microarray analysis uncovers retinoid targets in human bronchial epithelial cells.

Ma Y, Koza-Taylor PH, DiMattia DA, Hames L, Fu H, Dragnev KH, Turi T, Beebe JS, Freemantle SJ, Dmitrovsky E.

Oncogene. 2003 Jul 31;22(31):4924-32.

PMID:
12894236
46.

Cyclin D1 as a target for chemoprevention.

Petty WJ, Dragnev KH, Dmitrovsky E.

Lung Cancer. 2003 Aug;41 Suppl 1:S155-61. Review.

PMID:
12867074
47.

Lung cancer prevention: the guidelines.

Dragnev KH, Stover D, Dmitrovsky E; American College of Chest Physicians.

Chest. 2003 Jan;123(1 Suppl):60S-71S.

PMID:
12527565
48.

Cyclin proteolysis as a retinoid cancer prevention mechanism.

Dragnev KH, Freemantle SJ, Spinella MJ, Dmitrovsky E.

Ann N Y Acad Sci. 2001 Dec;952:13-22. Review.

PMID:
11795432
49.

Evidence for the epidermal growth factor receptor as a target for lung cancer prevention.

Lonardo F, Dragnev KH, Freemantle SJ, Ma Y, Memoli N, Sekula D, Knauth EA, Beebe JS, Dmitrovsky E.

Clin Cancer Res. 2002 Jan;8(1):54-60.

50.

Retinoic acid activates p53 in human embryonal carcinoma through retinoid receptor-dependent stimulation of p53 transactivation function.

Curtin JC, Dragnev KH, Sekula D, Christie AJ, Dmitrovsky E, Spinella MJ.

Oncogene. 2001 May 3;20(20):2559-69.

Supplemental Content

Loading ...
Support Center